Home > Inhibitors & Agonists

Inhibitors & Agonists

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC4196 Pm00104 Potent anticancer tetrahydroisoquinoline alkaloid, being able to form a covalent bond with the amino group of a guanine in selected triplets of DNA duplexes and eventually give rise to double-strand breaks
DCC4197 Pmed-1 Novel inhibitor of β-catenin signaling, significantly reduced β-catenin activity in hepatoblastoma and several HCC cells
DCC4198 Pmmb-317 Novel potent irriversible dual inhibitor of tubulin and epidermal growth factor receptor (EGFR), inducing the apoptosis of A549 cells in a dose- and time-dependent manner, along with decrease in mitochondrial membrane potential (MMP), production of ROS an
DCC4199 Pmpmease-in L-23 Novel inhibitor of prenylated methylated protein methyl esterase (PMPMEase), a key enzyme in the reversible methylation/demethylation step in the protein prenylation pathway
DCC4200 Pmpmease-in L-28 Novel inhibitor of prenylated methylated protein methyl esterase (PMPMEase), a key enzyme in the reversible methylation/demethylation step in the protein prenylation pathway
DCC4201 P-mppf Dihydrochloride Selective 5-HT1A serotonin receptor antagonist
DCC4202 P-nitro-pifithrin-α Cell-permeable analog of pifithrin-α, potently blocking p53-mediated expression of p21/WAF1 and apoptosis
DCC4203 Pnr-4-20 Novel G Protein-Biased Cannabinoid 1 (CB1) Receptor Agonist
DCC4204 Pnu-292137 Potent inhibitor of CDK2/cyclin A
DCC4205 Pnu-69176e Allosteric modulator of 5-HT(2C)R with no intrinsic agonist activity
DCC4206 Pnz-tmp The first small-molecule approach capable of detecting and controlling engineered cell-cell outputs
DCC4207 Podoverine A Novel microtubule destabilizing natural product from the Podophyllum species
DCC4208 Pol I Inhibitor T5 Novel RNA polymerase I inhibitor, targeting ribosomal DNA G-quadruplexes, potently and selectively inhibiting cell growth by high-affinity binding to G4s in ribosomal DNA, impairing RNA polymerase I (Pol I) elongation, inducing a rapid inhibition of Pol I
DCC4209 Pol7001 Novel macrocycle antibiotic with selective and potent activity against P. aeruginosa
DCC4210 Poloppin-ii Novel modulator of protein-protein interactions of the mitotic polo-like kinases, targeting KRAS mutant xenografts, indicate avenues, acting synergistically with Crizotinib, an inhibitor of the c-MET receptor, against mutant KRAS-expressing cancer cells
DCC4211 Poloxipan Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis
DCC4212 Poly(ethyleneimine) Solution Used for the transfection of a broad variety of cell lines; Antimicrobial; Novel binding agent of diffusive gradients in thin-films (DGT) technique (PEI-DGT)
DCC4213 polygonatone D Novel activator of Adenosine monophosphate (AMP)-activated protein kinase (AMPK)
DCC4214 Polymyxin Antibiotic as a last-line therapy to treat infections caused by these life-threatening 'superbugs'
DCC4215 polyphenol 13b Novel pan-inhibitor of KCa3.1/KCa2 channels
DCC4216 Pom2-c-hmbp Potent Activator of Vγ9Vδ2 T-Lymphocytes; HMBPP ananlog prodrug
DCC4217 Ponfibrate Hypobetalipoproteinemic and Lipid decreasing agent
DCC4218 Poziotinib Hydrochloride Novel pan-human EGF receptor (HER) inhibitor
DCC4219 Ppa250 Novel iNOS homodimerization inhibitor
DCC4220 Pparalpha/delta-in-11 The first reported PPARα/δ dual antagonist
DCC4221 Pparalpha/gamma Agonist N15 Novel dual PPARα/γ agonist, ameliorating insulin resistance and gluconeogenesis in vivo and vitro
DCC4222 Ppi Inhibitor-i Novel inhibitor of protein-protein interaction (PPI), blocking #212121; font-family: BlinkMacSystemFont, -apple-system, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", sans-serif; font-size: 14px; font-style: no
DCC4223 pp-ii-a03 Novel insulin mimetic
DCC4224 Ppi-in-3344 Novel pan-RAS-effector PPI inhibitor
DCC4225 Ppk1-in-17 Novel PPK1 inhibitor, preventing UTI effectively through the disruption of the PPK1 function

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X
>